Beipuao Biotech Secures Tens of Millions in Pre-A Funding to Advance Breakthrough Proteomics Technologies for Precision Medicine in Major Diseases

VCBeat has learned that Shenzhen Beipuao Biotechnology Co., Ltd. (“Beipuao”) recently completed a Pre-A financing round worth tens of millions of RMB. The round was led by Qiming Venture Partners, with participation from funds under CICC Capital and the company’s angel-round investor, GL Ventures. The proceeds will be primarily used to expand the market for its products and services, rapidly iterate products based on market demand, and provide enterprises with comprehensive solutions.

Beipuao, established in January 2022, is a high-tech R&D company specializing in proteomics. Dedicated to the commercial development and translation of R&D achievements in the field of proteomics, Beipuao leverages its patented series of proteomic sample pre-treatment products as an entry point to provide customers with end-to-end solutions through its clinical functional proteomics technology platform.

Beipuao’s core team has accumulated extensive technical expertise in proteomics methodology and applied research. In 2016, after years of in-depth investigation, the team pioneered the innovative SISPROT integrated sample preparation technique for proteomics. This approach consolidates all proteomic sample preparation steps into a miniaturized solid-phase extraction column, thereby minimizing sample loss during transfer steps and significantly reducing the total processing time.

Leveraging this technology, Beipuao has developed and launched a commercial product—the SISPROT Fully Integrated Proteomics Sample Preparation Kit. The SISPROT kit is suitable for the analysis of ultra-trace clinical samples. Through its one-stop sample preparation workflow, it enables the stable detection of approximately 6,000 proteins from an initial sample amount of 100 nanograms, outperforming comparable products in terms of detection sensitivity, analytical efficiency, and throughput. Additionally, to meet the analytical demands of large-scale clinical cohorts, Beipuao has developed an automated, high-throughput sample preparation instrument with independent intellectual property rights. This instrument can be used in conjunction with the SISPROT kit to automate all steps of proteomic sample preparation, enabling the processing of 96 samples within two hours, thereby significantly enhancing efficiency while ensuring high consistency.

▲Figure Group: SISPROT Proteomics Sample Preparation Kit Products (Left Image)

Complete Solution for Spatially Resolved Proteomics (Right Figure)

Based on its proprietary SISPROT sample preparation technology,Beipuao has gradually launched multiple proteomics technology solutions to meet the requirements for ultra-trace sample preparation, including spatially resolved proteomics and cell-type-specific proteomics.Provides a powerful multi-strategy tool for systematic analysis of the tissue microenvironment, offering strong competitive advantages in the market.Dr. Gao Weina, Chief Technology Officer of BeipuaoIntroduction: "Beipuao positions itself as an upstream technology solutions provider for the entire proteomics market, filling a commercial gap in this field. It can form a complete upstream-downstream industrial chain with various types of domestic and international proteomics companies and the biomedical industry chain, thus offering broad market prospects."

Regarding Beipuao's future development plans,Dr. Xu Hao, CEO of Beipiaostated: “We extend our gratitude to the investors for their recognition and support of Beipuao. This round of financing marks a significant milestone in the company’s development. With the successful completion of this funding round, Beipuao’s SISPROT kit for proteomics sample pre-treatment has achieved mass production and entered the commercialization phase, thanks to the team’s concerted efforts and highly efficient R&D. The fully automated workstation has completed internal testing and is expected to enter the market in the second half of 2023. Furthermore, we have established platforms for spatially resolved proteomics and cell-resolution proteomics. Looking ahead, Beipuao will leverage its base in the Greater Bay Area, aiming to play a more substantial role in the entire innovation chain of novel biomarker discovery and innovative drug development.”

Dr. Kan Chen, Partner at Qiming Venture Partnersstated: “We pay close attention to innovative enterprises in the field of proteomics. In recent years, proteomics technologies have advanced rapidly, and the next 5–10 years are expected to be a golden period for explosive growth in the proteomics sector both in China and globally. Correspondingly, companies involved in proteomics are entering a phase of rapid development. Beipuao is currently at the take-off stage of its business development. We are optimistic about Beipuao’s future prospects and hope that, through the joint efforts of its core team, the company can quickly grow into an industry benchmark, leveraging leading-edge proteomics technologies to advance precision medicine and create greater value for society.”

Since the concept of proteomics was proposed, it has undergone more than two decades of rapid development and has become one of the core components of precision medicine research. Currently, it is widely applied in biomedical research, particularly providing more precise and reliable information for the discovery of early diagnostic biomarkers for cancer, drug target screening, disease subtyping and personalized medication, as well as therapeutic efficacy assessment.

Due to the high complexity of the proteome, current research still faces numerous challenges. Among these, the time-consuming nature of proteomic sample preparation has imposed significant limitations on the widespread application of proteomics. Cellular proteins must undergo a series of rigorous and cumbersome procedures—including lysis and extraction, reduction and alkylation, enzymatic digestion, and desalting—before pure, impurity-free, high-concentration peptides can be obtained for mass spectrometry analysis. Consequently, existing sample preparation techniques struggle to achieve in-depth qualitative and quantitative analysis for trace amounts of complex protein samples, particularly large-scale clinical cohort samples. Therefore, there is an urgent demand from both researchers and the market for simpler, faster, and more stable proteomic sample preparation technologies.

In 2016, the founder led the team to innovatively propose the SISPROT fully integrated proteomics sample preparation technology for the first time after years of in-depth research. Its advantage lies in integrating all proteomic sample preparation steps into a miniaturized solid-phase extraction column, which not only reduces sample loss during transfer steps but also significantly shortens the total operation time.

To translate scientific research achievements from the laboratory to clinical market applications, SISPROT technology has undergone industrialization exploration at Beipuao, leveraging this core technology for further R&D and transformation into commercial products—SISPROT Proteomic Sample Preparation Kit.

The SISPROT kit primarily features the following technical characteristics:

• 1. Sample preparation time can be reduced from the traditional 10+ hours to just 2 hours, improving detection efficiency by over 90%;

• 2. SISPROT KitIt enables a one-stop completion of all steps in proteomics sample preparation starting from trace amounts of clinical and other biological samples, with the processed samples being directly compatible with chromatography-mass spectrometry analysis.Significantly reduces the loss of trace samples during operation, enabling stable detection of approximately 6,000 proteins from an initial sample amount of 100 nanograms;

• 3. Excellent quantitative stability is achieved across different batches and operators. Therefore, the SISPROT kit outperforms comparable products in both detection sensitivity and analytical throughput. The new-generation SISPROT kit has currently reached mass production and entered the commercialization phase.

Furthermore, in response to the analytical needs of large-scale clinical cohorts,Beipuao has developed a fully automated, high-throughput sample preparation instrument with independent intellectual property rights. It is compatible with all steps of proteomic sample preparation using the SISPROT kit, enabling the processing of 96 samples within 2 hours, which significantly enhances efficiency while ensuring high consistency.. The research and development of the fully automated workstation has completed internal testing, with market entry expected in the second half of 2023.

▲Fig. SISPROT Proteomics Sample Preparation Kit Product

The Beipuao team possesses a robust foundation in researching the mechanisms of the tumor microenvironment. Leveraging its proprietary SISPROT sample preparation technology, the company has progressively launched multiple proteomics technical solutions that meet the requirements for ultra-trace sample preparation. These solutions, including spatially resolved proteomics and cell-type-specific proteomics, provide powerful multi-strategic tools for deciphering tissue microenvironments, thereby establishing a strong competitive advantage in the market.

Cells and the extracellular matrix collectively constitute a highly heterogeneous tissue microenvironment, whose spatial distribution is closely associated with intercellular signal transduction networks and plays a crucial regulatory role in the pathogenesis of major diseases such as cancer. Spatial transcriptomics technologies have matured into commercial products and are widely applied; however, due to limitations in sample pretreatment techniques, there remains a lack of proteomic analysis strategies that combine discovery capability with high spatial resolution. To address these technical bottlenecks,Bepu Launches End-to-End Solution for Spatially Resolved Proteomics Visualization,By leveraging our proprietary SISPROT fully integrated proteomics sample preparation technology and high-sensitivity analytical techniques, we can achieve qualitative and quantitative analysis of the tissue microenvironment at specific spatial locations within pathological sections, both at the imaging and protein expression levels.Implement a comprehensive spatial proteomics solution that includes automated identification, isolation, sample pre-processing, and data analysis at single-cell resolution. The detection sensitivity of the proteomics platform enables the identification of over 7,000 proteins from a 0.1 mm² FFPE section using multiplex fluorescence immunostaining.

Currently, the identification capability of existing cell type-based proteomic methods on the market cannot match that of single-cell transcriptomics. This is mainly due to insufficient capabilities in micro-sample pretreatment and limitations such as the analytical throughput of mass spectrometry, which prevent the commercial realization of deep proteomic identification.Beipuao Launches Cell-Resolution Proteomics Solution for Deep Protein Identification from Trace Cell SamplesBeipuao has launched a cell-resolution proteomics solution that enables deep protein identification from trace amounts of cells. This technology facilitates proteomic analysis of more than 10 cell types in clinical blood and tissue samples, allowing the identification of over 6,000 proteins from fewer than 1,000 cells.

▲ Figure: Complete Solution for Spatially Resolved Proteomics Visualization